Trajan Joins BioMelbourne Network
News Feb 04, 2014
Trajan Scientific and Medical is now a member of BioMelbourne Network. As a group of companies with headquarters in Melbourne, Trajan is looking forward to strengthening connections with local scientific organisations, business leaders and government.
Stephen Tomisich, Trajan’s Chief Executive Officer said, “We hope our membership helps us to engage with other members to support and contribute to the success of the Australian scientific industry, in particular biotechnology in Victoria.
“We are proud to be an Australian owned and operated global company, building on humble beginnings in Ringwood with SGE Analytical Science over 50 years ago, growing to develop new analytical technologies for the scientific community and society.”
Trajan’s focus is on developing and commercializing technologies that enable analytical systems to be more selective, sensitive and specific for biological, environmental or food related measurements, especially those that can lead to portability, miniaturization and affordability.
“We seek opportunities for each of our companies with their unique capabilities. Trajan is able to facilitate collaboration with one or more of our companies in Australia and around the world.” said Robert Lyon, Head of Corporate Development at Trajan.
Trajan encompasses a group of companies including SGE Analytical Science, Grale HDS and SciMed Precision with over 300 staff worldwide, and customers in over 100 countries.
SGE Analytical Science is a world leader in creating components and consumables used in scientific analysis. SGE has substantial capability in materials science, chemistry, fabrication and distribution.
SciMed Precision offers complete solutions in design and production engineering of high precision complex components for analytical and life science applications.
Grale HDS is a pathology supply partner like no other. Supplying quality products for more than 30 years, they assist laboratory managers tackle operational challenges.
“Through true customer focus and partnerships, we aim to make a positive impact on the world of analytical and medical science.” said Mr Tomisich.
The EU's policy on genetically modified organisms (GMO's) is extremely strict and prevents new GMO crops from being authorized. The policy is based on arguments about the risk and unnaturalness of GMO plants - but these arguments cannot justify the restrictive regulation, three researchers conclude in a new study.READ MORE